Your browser doesn't support javascript.
loading
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
Zeissig, Sebastian; Rosati, Elisa; Dowds, C Marie; Aden, Konrad; Bethge, Johannes; Schulte, Berenice; Pan, Wei Hung; Mishra, Neha; Zuhayra, Maaz; Marx, Marlies; Paulsen, Maren; Strigli, Anne; Conrad, Claudio; Schuldt, Dörthe; Sinha, Anupam; Ebsen, Henriette; Kornell, Sabin-Christin; Nikolaus, Susanna; Arlt, Alexander; Kabelitz, Dieter; Ellrichmann, Mark; Lützen, Ulf; Rosenstiel, Philip C; Franke, Andre; Schreiber, Stefan.
Afiliação
  • Zeissig S; Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Rosati E; Center for Regenerative Therapies Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Dowds CM; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Aden K; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Bethge J; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Schulte B; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Pan WH; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Mishra N; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Zuhayra M; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Marx M; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Paulsen M; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Strigli A; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Conrad C; Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Schuldt D; Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Sinha A; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Ebsen H; Department of Medicine I, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Kornell SC; Center for Regenerative Therapies Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Nikolaus S; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Arlt A; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Kabelitz D; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Ellrichmann M; Institute of Immunology, Christian-Albrechts-Universität zu Kiel, Kiel, Germany.
  • Lützen U; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Rosenstiel PC; Institute of Clinical Molecular Biology, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Franke A; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Schreiber S; Department of Internal Medicine I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Gut ; 68(1): 25-39, 2019 01.
Article em En | MEDLINE | ID: mdl-29730603
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Doenças Inflamatórias Intestinais / Imunidade Adaptativa / Anticorpos Monoclonais Humanizados / Imunidade Inata Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Gut Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fármacos Gastrointestinais / Doenças Inflamatórias Intestinais / Imunidade Adaptativa / Anticorpos Monoclonais Humanizados / Imunidade Inata Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male Idioma: En Revista: Gut Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido